



September 10, 2025

**WASHINGTON, DC** – The Alliance for Longevity Initiatives (A4LI) is proud to announce the **Longevity Investors Summit**, taking place during **LA Tech Week 2025 presented by a16z**. This gathering will spotlight pioneering biotechnology companies leveraging **artificial intelligence to extend human healthspan**.

The Summit is designed to bridge the gap between **investors, entrepreneurs, and the general public**, while also **bringing together experts and companies from both San Francisco and Los Angeles** who are driving breakthroughs in the longevity space. By aligning with LA Tech Week, the event taps into a broader movement of **grassroots energy and collaboration**, amplifying the visibility of promising companies that are redefining what it means to live healthier, longer lives.

“A4LI’s mission is to accelerate the field of longevity science through advocacy and visibility,” said Dylan V. Livingston, Founder and CEO of A4LI. “Hosting this summit during LA Tech Week not only spotlights groundbreaking companies, but also fosters connections between the Bay Area and Southern California — uniting two hubs of innovation to drive the field forward.”

The **Longevity Investors Summit** will feature company presentations, investor networking, and interactive discussions exploring how AI is transforming the future of medicine and human wellness. **Check out the full program here:** <https://a4li.org/a4li-longevity-investors-summit/>.

### **Media Inquiries**

For more information or for media requests, please reach out to our support team at [info@a4li.org](mailto:info@a4li.org).

### **About the Alliance for Longevity Initiatives (A4LI)**

The Alliance for Longevity Initiatives (A4LI) is an independent 501(c)(4) nonprofit organization committed to advancing legislation and policies that promote healthy human lifespan. With a focus on equitable access to next-generation therapies, A4LI brings together scientists, policymakers, and influencers to drive collaboration and innovation in the longevity biotech industry.